Is JNCE or RYLD a better dividend investment in 2026?

JNCE currently yields 106.38% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: JNCE offers higher current income.

What is the dividend yield difference between JNCE and RYLD?

JNCE has a forward dividend yield of 106.38% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 94.24 percentage points.

Home › Compare › JNCE vs RYLD

JNCE vs RYLD: Dividend Comparison 2026

JNCE yields 106.38% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 JNCE wins by $5.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

JNCE

● Live price

106.38%

Share price

$1.88

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$5.04M

Annual income

$1,769,060.94

Full JNCE calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — JNCE vs RYLD

📍 JNCE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	JNCE	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, JNCE + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

JNCE pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNCE

Annual income on $10K today (after 15% tax)

$9,042.55/yr

After 10yr DRIP, annual income (after tax)

$1,503,701.80/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, JNCE beats the other by $1,501,502.55/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNCE + RYLD for your $10,000?

JNCE: 50%RYLD: 50%

100% RYLD50/50100% JNCE

Portfolio after 10yr

$2.54M

Annual income

$885,824.14/yr

Blended yield

34.84%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNCE right now

JNCE

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Altman Z

0.6

Piotroski

3/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNCE buys

RYLD buys

No recent congressional trades found for JNCE or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricJNCERYLD

Forward yield	106.38% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$5.04M	$44.5K ✓
Annual income after 10y	$1,769,060.94 ✓	$2,587.35
Total dividends collected	$4.53M	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: JNCE vs RYLD ($10,000, DRIP)

Year	JNCE Portfolio	JNCE Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$21,338	$10,638.30	$11,914	$1,213.65	+$9.4K → JNCE
2	$44,047	$21,215.25	$14,099	$1,351.30	+$29.9K → JNCE
3	$88,059	$40,928.25	$16,580	$1,494.55	+$71.5K → JNCE
4	$170,693	$76,470.42	$19,384	$1,642.61	+$151.3K → JNCE
5	$321,175	$138,533.11	$22,535	$1,794.70	+$298.6K → JNCE
6	$587,267	$243,609.90	$26,063	$1,950.00	+$561.2K → JNCE
7	$1,044,675	$416,298.80	$29,995	$2,107.69	+$1.01M → JNCE
8	$1,809,898	$692,096.64	$34,361	$2,266.99	+$1.78M → JNCE
9	$3,057,206	$1,120,614.24	$39,194	$2,427.12	+$3.02M → JNCE
10	$5,040,271	$1,769,060.94	$44,525	$2,587.35	+$5.00M → JNCE

JNCE vs RYLD: Complete Analysis 2026

JNCE — Stock

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Full JNCE Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this JNCE vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNCE vs SCHD JNCE vs JEPI JNCE vs O JNCE vs KO JNCE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.